As per the estimation on recent research, 80 to 150 million people are affected by Hepatitis C infection worldwide.
In fact, it has a great impact on low and medium-income countries like Africa and Asia. However, hepatitis C is infected related to liver disease and is estimated to be half a million per annum. Therefore, this consists of a good approach in solving the interferon-based for two decades and increasing HCV treatment.
Fortunately, recent years have seen a better resolution against HCV therapeutic development to consider the HCV protease disease. This is extremely high efficacy.
It has been used in various combinations like HCV genotypes and previous treatment for the affected people in low-income countries.
Personal importation of hepatitis C therapies
In some lower-income countries including India, voluntary licenses have been issued clearly and allow Indian manufacturers to make generic versions of medicine and market them.
In India, 11generic companies have signed a voluntary license for these medicines with Gilead Sciences and based on the low and middle-income countries around the world.
Many patients around the world prefer Indian generic hepatitis c medicine for their cure because the quality, strength and cure rate is the same as branded Harvoni, Epclusa.